P
CYTK icon

&Partners’s Cytokinetics CYTK Stock Holding History

&Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$333K Buy
3,913
+334
+9% +$24K ﹤0.01% 2072
2026
Q1 		$236K Sell
3,579
-57
-2% -$3.62K ﹤0.01% 2150
2025
Q4 		$231K Buy
+3,636
New +$226K ﹤0.01% 2065

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

&Partners's CYTK Position: Q2 2026 in Review

&Partners increased its Cytokinetics (CYTK) stake by 9.3% in Q2 2026, buying an estimated $24K and bringing the position to 3,913 shares worth $333K. The position accounts for ﹤0.01% of the portfolio, ranked #2072.

&Partners first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • &Partners held 3,913 shares of Cytokinetics worth $333K as of Q2 2026.
  • &Partners bought 334 Cytokinetics shares in Q2 2026, an estimated $24K.
  • Cytokinetics made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2072 holding.
  • &Partners first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.